BioCentury
ARTICLE | Clinical News

Amylin Phase II AC2993 data

September 19, 2001 7:00 AM UTC

AMLN said its AC2993 synthetic exendin-4 stimulated insulin secretion and lowered fasting plasma glucose in a dose dependent manner in the three doses studied in combination with existing therapy. The...